Annelien Van Dalem

Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and <i>HLA-DQ</i> Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes

Frans Gorus, Eric V. Balti, Anissa Messaaoui et al. · Diabetes Care · 2017 · 62 citations

Life Sciences, Endocrinology, Genetics +17

Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients

Frans Gorus, Eric V. Balti, Ilse Vermeulen et al. · Clinical & Experimental Immunology · 2012 · 48 citations · Full text

Life Sciences, Endocrinology, Immunology +16

<i>In Vitro</i> Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam

Annelien Van Dalem, Margaux Herpol, Fedoua Echahidi et al. · Antimicrobial Agents and Chemotherapy · 2018 · 44 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +11

Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes

Simke Demeester, Bart Keymeulen, Leonard Kaufman et al. · Diabetes Care · 2015 · 30 citations · Full text

Life Sciences, Endocrinology, Immunology +17

<i>HLA-A*24</i> Is an Independent Predictor of 5-Year Progression to Diabetes in Autoantibody-Positive First-Degree Relatives of Type 1 Diabetic Patients

Eric Mbunwe, Bart Van Der Auwera, Ilse Vermeulen et al. · Diabetes · 2012 · 27 citations · Full text

Life Sciences, Genetics, Immunology +17